TRISCEND II: Novel Randomized Trial Design for Transcatheter Tricuspid Valve Replacement.
Am J Cardiol
; 225: 171-177, 2024 Aug 15.
Article
in En
| MEDLINE
| ID: mdl-38897265
ABSTRACT
Severe tricuspid regurgitation remains largely undertreated given limited treatment options. Transcatheter tricuspid valve interventions have emerged as a promising therapy for these patients, and the TRISCEND II pivotal trial is the first randomized controlled trial to evaluate transcatheter tricuspid valve replacement (TTVR). The TRISCEND II pivotal trial studies the transcatheter EVOQUE (Edwards Lifesciences, Irvine, California) tricuspid valve replacement system using a United States Food and Drug Administration Breakthrough Device Designation-a program intended to provide timely access to medical devices by speeding up development, assessment, and review. The TRISCEND II trial is a prospective, multicenter trial that randomizes patients with symptomatic severe tricuspid regurgitation to treatment with either TTVR in conjunction with optimal medical therapy or optimal medical therapy alone. The trial's novel 2-phase design evaluates 30-day safety and 6-month effectiveness end points for the first 150 patients in the initial phase and a 1-year safety and effectiveness end point for the full cohort of 400 patients in the second phase. The TRISCEND II trial's 2-phase trial design provided an opportunity for early review and led to the first commercial approval of a TTVR system. In conclusion, the design of the TRISCEND II trial will likely inform future transcatheter tricuspid device trials.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Tricuspid Valve
/
Tricuspid Valve Insufficiency
/
Cardiac Catheterization
/
Heart Valve Prosthesis Implantation
Limits:
Humans
Language:
En
Journal:
Am J Cardiol
Year:
2024
Document type:
Article